GROUP C (2011) | GROUP C (2014) | p-value | |||
---|---|---|---|---|---|
patients (n) | total | 1083 | n/a | ||
gender (%) | male | 584 (53.9%) | n/a | ||
female | 470 (43.4%) | ||||
undetermined | 29 (2.7%) | ||||
age (years) | Median (IQR) | 75 (68–81) | 78 (71–84) | n/a | |
Min – Max | 24–93 | 27–96 | |||
< 65 | 200 (18.5%) | 145 (13.4%) | |||
65–74 | 321 (29.6%) | 241 (22.3%) | |||
≥75 | 562 (51.9%) | 697 (64.4%) | |||
additional diagnosis | patients With at least 1 | 1003 (92.6%) | 986 (91.0%) | .13a | |
renal insufficiency | 61 (5.6%) | 65 (6.0%) | .77a | ||
coagulopathy | 17 (1.6%) | 17 (1.6%) | 1.0a | ||
intracranial bleeding | 4 (0.4%) | 5 (0.5%) | 1.0a | ||
epistaxis | 21 (1.9%) | 14 (1.3%) | .30a | ||
gastrointestinal bleeding | 13 (1.2%) | 17 (1.6%) | .59a | ||
stroke | 33 (3.0%) | 28 (2.6%) | .58a | ||
CHA2DS2-VASC: | 0 | 92 (8.5%) | 59 (5.4%) | <.01a | |
1 | 100 (9.2%) | 87 (8.0%) | |||
≥2 | 884 (81.6) | 908 (83.8%) | |||
not computable | 7 (0.6%) | 29 (2.7%) | n/a | ||
prescriptions (per year) | total | 1056 (97.5%) | 1064 (98.2%) | n/a | |
M (SD) | 19.4 (14.6) | 22.6 (16.5) | <.01b | ||
Min - Max | 1–118 | 1–115 | |||
all patients including those without prescription | <.01b | ||||
M (SD) | 18.8 (14.8) | 22.0 (16.7) | |||
Min - Max | 0–118 | 0–115 | |||
OAC1 | VKA or NOAC | 382 (35.3%) | 600 (55.4%) | <.01a | |
VKA | 373 (34.4%) | 387 (35.7%) | .41a | ||
Rivaroxaban | 3 (0.3%) | 181 (16.7%) | <.01a | ||
Dabigatran | 7 (0.6%) | 23 (2.1%) | <.01a | ||
Apixaban | none | 28 (2.6%) | n/c | ||
ASA (without additional OAC)2 | 136 (12.6%) | 97 (9.0%) | <.01a | ||
consultation of cardiologist | 245 (22.6%) | 262 (24.2%) | .32a |